INmune Bio Announces $13.0 Million Registered Direct Offering

Stock Information for INmune Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INmune Bio Inc.

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
INKmune(TM) Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro(TM) on Proteins that Regulation Synapses in Alzheimer's Patients
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune(TM) in the Journal for ImmunoTherapy of Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.